...mos; actuarial median OS (events:61%): 4 mos. Evaluation of clinical benefit is ongoing.,The weekly schedule of O-VNB is...
...MOs responded. Correlative testing of bx specimens was considered worthwhile by 96% of MOs. Clinical trials with mandato...
...mos of AST, for pts with clinically localized prostate cancer. Quality-of-life utility measures and cost data were obtai...
...mos, range 2 to 15. Mean TTPd 7.9 +/- 4.0 mos, range: 2 - 20. Twelve deaths has been registered (63.1%). Mean survival: ...
886 Background: IBC is the most aggressive form of breast cancer. The introduction of chemotherapy(CT) in multimodality ...
...mos. vs 7 mos. for the entire population, 14.1 mos. vs 9 mos. for responders, and 6.1 mos. vs. 5 mos. for non-responders...
...mos, MST is 12.1 mos with est. 1- & 2-yr OS rates of 50.2% (95% CI: 40.0, 59.6) & 25.9% (17.3, 35.3). Median & 1-yr PFS ...
...MOS) after the start of CLD-IEP for all 37 pts was 17.5 months (range, 2.7 to 61.5). MOS was 20.8 months in the responde...
...mos.,the remaining pt with humeral and shoulder soft tissue involvement has important radiological and physical improvem...
...mos (range 1.8-7.5). Median time to progression was 4.4 mos (95% CI: 2.7-5.6), and the median survival was 5.7 mos (95% ...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269